Ratings Alligator Bioscience AB

Equities

ATORX

SE0000767188

Delayed Nasdaq Stockholm Other stock markets 05:28:15 2024-04-30 am EDT			5-day change	1st Jan Change
0.906 ^SEK	-2.05%		-8.54%	+30.62%

Apr. 26	Alligator Bioscience and Orion Corporation Announces Exercise of Development Option Under 2021 Research Collaboration and License Agreement	CI
Apr. 05	Alligator Bioscience AB Announces Graham Dixon and Veronica Wallin Not Proposed for Re-Election on Board	CI

Summary

From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

Over the past year, analysts have regularly revised upwards their sales forecast for the company.
Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.

Weaknesses

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
The company has insufficient levels of profitability.
The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
For the last few months, analysts have been revising downwards their earnings forecast.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
ALLIGATOR BIOSCIENCE AB	+30.62%	64.16M	C+
IQVIA HOLDINGS INC.	+1.77%	42.86B	B
LONZA GROUP AG	+45.43%	41.36B	A
MODERNA, INC.	+12.24%	42.74B	B-
CELLTRION, INC.	-8.83%	27.68B	C
ICON PUBLIC LIMITED COMPANY	+7.44%	25.15B	B-
ALNYLAM PHARMACEUTICALS, INC.	-23.01%	18.63B	B
MEDPACE HOLDINGS, INC.	+30.56%	12.37B	C+
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.82%	11.92B	C+
UNITED THERAPEUTICS CORPORATION	+8.35%	11.21B	B+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes